Navigation Links
Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
Date:1/28/2008

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced that in a special meeting today shareholders approved the proxy proposal amending and restating the Company's articles of incorporation to increase the number of authorized shares from 110 million to 210 million and to increase the number of authorized shares of common stock from 100 million to 200 million.

Louis A. Bianco, Chief Financial Officer at CTI, who chaired the meeting, said "The increase in the number of authorized shares of common stock provides CTI with flexibility needed to support the future growth of the business. I'd like to thank all of the shareholders who returned their proxies."

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include risks related to the impact of the increase in authorized shares of stock and the future business growth of the Company as well as the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
3. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
4. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
5. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
6. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
7. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
8. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
9. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
10. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... Research and Markets  has announced the addition of ... Report" report to their offering. This report ... US$ Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... 22 Edwards Lifesciences,Corporation (NYSE: EW ... of heart valves,today announced the opening of ... North Crescent, Singapore. The state-of-the-art facility produces,Edwards, ... also serves as the headquarters for Edwards, ...
... 22 Celldex,Therapeutics (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: ... product,candidate, CDX-110, being developed for the treatment of ... oral presentation at the 44th,Annual Meeting of the ... will be held at McCormick Place in Chicago ...
... to Add Valuable Clinical Development Expertise, SAN ... company focused on the development of novel Toll-Like,Receptor ... respiratory and,autoimmune diseases, announced today the appointment of ... "We are pleased to have Elliott join our ...
Cached Biology Technology:Edwards Lifesciences Opens New Singapore Heart Valve Facility 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors 2
(Date:8/20/2014)...  The second annual Biometrics UnPlugged Executive Summit, ... Florida on September 15, 2014, will ... and Strategy at Samsung, and Philippe de Raet, Vice ... this year,s event is Mobility at the Crossroads ... UnPlugged: Mobility at the Crossroads of Commerce & ...
(Date:8/19/2014)... 19, 2014 To improve students, chances of ... the University of Houston (UH) implemented a comprehensive ... at risk for failure. , Through a ... (THECB), the Department of Biology and Biochemistry embarked ... taking "General Biology" for non-majors and "Introductory Biology" ...
(Date:8/19/2014)... German . ... If a large amount of electricity is to be produced ... have to be stored during productive periods so that these ... far from adequate for the purpose. Science and industry are ... on battery systems that used to be too expensive or ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... Boston, MA Using 120 years of feathers ... University researchers have been able to track increases in ... nigripes ), an endangered seabird that forages extensively throughout ... the observed increase in methylmercury levels, most likely from ...
... University of the Negev software engineering students have developed ... computer without using a keyboard or mouse only ... to develop devices to read brainwaves and operate specific ... a laboratory setting. The BGU ...
... April 18, 2011 Mention vitamin D-fortified foods and ... with the sunshine vitamin since the 1930s. A new ... Challenges/Chemistry Solutions" podcast series says that vitamin D-fortified bread ... essential nutrient that is difficult to get naturally in ...
Cached Biology News:Mercury on the rise in endangered Pacific seabirds 2
...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... mix (Thermoprime Plus DNA Polymerase with a ... times higher fidelity than standard Taq DNA ... DNA polymerase, Amplifies DNA templates >20kb, Concentration: ... PCR for cloning and mutagenesis We are ...
... EnzChek Lysozyme Assay Kit (E-22013) provides,researchers ... levels of lysozyme,activity in solution. This ... to 20 U/mL (Figure 1). The ... cell,walls, which are labeled to such ...
Biology Products: